ESMO 2021 Solid Tumors – Yelena Y. Janjigian
Yelena Y. Janjigian talks about the practice-changing results obtained in the CheckMate 649 trial and how the proportion of patients with advanced gastric cancer and esophageal adenocarcinoma who receive multiple treatment lines rather than just one or two can be increased. Biomarker-targeted therapies, precision medicine approaches for advanced G/GEJ cancers, the significance of chemotherapy as well as the duration of maintenance therapy are discussed, too.
Here is the full ESMO 2021 Solid Tumors report.
More posts
Ovarian cancer: taking PARP inhibition one step further
Ovarian cancer: taking PARP inhibition one step further Individualized dosing o
Getting innovation from the laboratories into clinical practice
Getting innovation from the laboratories into clinical practice Andrés Cervantes
Milestones of PD-1 inhibition in gastric and esophageal cancer
Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer,
Preface – ESMO 2020 Solid Tumors
Preface – ESMO 2020 Solid Tumors Ronan Kelly, MD, MBA – Director of the
